TP53 and neoplasm: Tumours with a high proliferation index and eventually a high fraction of clonogens able to enter the phase of accelerated repopulation during CRT, as well as tumours with increased intrinsic radioresistance (e.g. mutations of p53 or c-erbB-2 gene amplification) have about 50% chance to recure after CRT; this seems to be averted using HypoARC.